email article
Interventional cardiologists offered a glimpse of what returning to normal looks like in countries that are currently beating back COVID-19. Here in 2021, at this point where all our staff are vaccinated, all our patients are vaccinated, the only difference in our clinical practice is that we continue to test every patient for COVID, said Ehtisham Mahmud, MD, of the University of California San Diego, (UCSD), during a panel discussion at Society for Cardiovascular Angiography and Interventions (SCAI) virtual meeting.
Coronavirus cases are trending down in the U.S., where nearly 40% of adults have been fully vaccinated. Mahmud noted that cath labs have returned to business as usual for 6-8 months already at UCSD.
Guest opinion: Why we decided to send our kids back to school
almanacnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from almanacnews.com Daily Mail and Mail on Sunday newspapers.
Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
Program Evaluated the Safety and Efficacy of Vadadustat in Adult Patients with Anemia Due to CKD on Dialysis and Not on Dialysis
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the
2VATE) and adult patients not on dialysis (PRO
2TECT) in two separate manuscripts.
Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is Akebia s lead product candidate. In late March 2021, the Company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vadadustat for the treatment of anemia due to CKD in both adult patients on dialysis
Vadadustat for Anemia in Chronic Kidney Disease: Questions Remain
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.